Cytokinetics, Incorporated $CYTK Shares Bought by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 6.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 215,952 shares of the biopharmaceutical company’s stock after acquiring an additional 13,512 shares during the period. Pinnacle Associates Ltd.’s holdings in Cytokinetics were worth $14,233,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in CYTK. Siren L.L.C. purchased a new stake in shares of Cytokinetics in the 1st quarter valued at approximately $40,466,000. Hsbc Holdings PLC boosted its position in shares of Cytokinetics by 5,906.5% during the 1st quarter. Hsbc Holdings PLC now owns 221,999 shares of the biopharmaceutical company’s stock worth $14,632,000 after purchasing an additional 218,303 shares during the period. Emerald Advisers LLC acquired a new stake in Cytokinetics in the 1st quarter valued at approximately $13,104,000. Candriam S.C.A. increased its holdings in Cytokinetics by 128.6% in the 1st quarter. Candriam S.C.A. now owns 335,208 shares of the biopharmaceutical company’s stock valued at $22,094,000 after purchasing an additional 188,577 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its holdings in Cytokinetics by 63.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company’s stock valued at $34,502,000 after purchasing an additional 157,700 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CYTK shares. Wall Street Zen lowered Cytokinetics from a “hold” rating to a “sell” rating in a research report on Tuesday. William Blair assumed coverage on Cytokinetics in a research report on Friday, October 16th. They set an “outperform” rating for the company. Mizuho lifted their price objective on Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, June 24th. Needham & Company LLC lifted their price objective on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, UBS Group reiterated a “buy” rating and issued a $104.00 price objective on shares of Cytokinetics in a report on Wednesday, October 14th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus target price of $105.44.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on Cytokinetics, providing continued analyst support for the company’s pipeline and commercial prospects. HC Wainwright rating report
• Positive Sentiment: Cytokinetics scheduled its third-quarter results for November 4, 2026, followed by a management conference call. The report will provide an important update on financial performance, aficamten commercialization and the company’s outlook. Cytokinetics third-quarter results announcement
• Neutral Sentiment: The company granted inducement awards covering 60,465 shares through stock options and 40,084 restricted stock units to 29 new employees. The grants support hiring but could modestly dilute existing shareholders over time. Cytokinetics inducement grants announcement
• Negative Sentiment: BofA Securities reduced its price target to $81 from $85 while maintaining a Neutral rating, signaling more limited near-term conviction even though the target remains above recent trading levels. BofA Securities price-target update
• Negative Sentiment: Wall Street Zen lowered Cytokinetics to a Sell rating, adding to concerns about valuation, execution and the company’s continuing losses. Wall Street Zen downgrade
• Negative Sentiment: Executive Vice President Fady Malik sold 3,500 shares for approximately $224,000. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, its bearish signaling value is limited, but it adds to the recent pattern of insider sales. SEC insider transaction filing

Insiders Place Their Bets

In other Cytokinetics news, CEO Robert Blum sold 7,500 shares of the business’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $62.88, for a total value of $471,600.00. Following the completion of the transaction, the chief executive officer owned 278,544 shares in the company, valued at $17,514,846.72. The trade was a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of the business’s stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $64.01, for a total transaction of $224,035.00. Following the completion of the transaction, the executive vice president owned 153,902 shares of the company’s stock, valued at approximately $9,851,267.02. This trade represents a 2.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 191,426 shares of company stock worth $13,543,855 in the last ninety days. 2.60% of the stock is owned by corporate insiders.

Cytokinetics Stock Performance

Shares of CYTK opened at $62.86 on Thursday. The company’s 50-day simple moving average is $69.38 and its 200-day simple moving average is $73.21. Cytokinetics, Incorporated has a 1 year low of $54.30 and a 1 year high of $88.31. The stock has a market capitalization of $7.82 billion, a PE ratio of -8.71 and a beta of 0.41.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. The company’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.12) EPS. On average, sell-side analysts predict that Cytokinetics, Incorporated will post -5.97 earnings per share for the current year.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.